Dr. Pemmaraju on Clinical Trial Results of LCL161 in High-Risk Myelofibrosis

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.

Among the 38 patients treated at the time of analysis, 10 were responding for an overall response rate of 24% to 26%, explains Pemmaraju. The median age is 72-years-old.

Five patients have experienced long-term responses, says Pemmaraju, with response rates over 1 year. The 3 most common side effects were fatigue, nausea, and dizziness—similar to what was seen with solid tumors.